Skip to content

Advertisement

  • Erratum
  • Open Access

Erratum to: Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus

  • 1Email author,
  • 2,
  • 1,
  • 1 and
  • 2
BMC Infectious Diseases20044:14

https://doi.org/10.1186/1471-2334-4-14

  • Received: 01 June 2004
  • Accepted: 01 June 2004
  • Published:

The original article was published in BMC Infectious Diseases 2004 4:1

Text

In our recent article [1], we did not declare the patent rights related to stampidine technology. Since they may potentially be viewed as non-financial competing interests despite the fact our employer is a non-profit public charity, we are now providing the following supplemental information:

FMU, AOV and HET are employees of Parker Hughes Institute, which has applied for a patent for the use of stampidine in the treatment of haemorrhagic fever. Parker Hughes Institute currently holds patents for the use of stampidine in other clinical conditions, with FMU listed as an inventor.

Notes

Authors’ Affiliations

(1)
Parker Hughes Center for Clinical Immunology, St. Paul, MN 55113, USA
(2)
Research Institute for Epidemiology and Microbiology, 220050 MINSK, Belarus

References

  1. Uckun FU, Petkevich AS, Vassilev AO, Tibbles HE, Titov LP: Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus. BMC Infect Dis. 2004, 4: 1-10.1186/1471-2334-4-1.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/4/14/prepub

Copyright

© Uckun et al; licensee BioMed Central Ltd. 2004

This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Advertisement